Early Phase 1 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be 18 years of age or older at the time of signing the consent form
- You have been diagnosed with an advanced solid tumor (such as pancreatic cancer or non-small cell lung cancer) that has been confirmed by a tissue or cell sample, and your cancer has gotten worse or you could not tolerate at least one previous treatment — in some cases, people who have not yet had any treatment may also be considered if the doctor believes they could benefit
- Your tumor must have a specific type of gene change (mutation) in a gene called KRAS that the trial is targeting
- You must be well enough to carry out basic daily activities, based on a standard health scoring system rated 0 to 2 (confirm with trial site)
- Doctors expect you to live for at least 12 weeks
- Your liver, kidneys, and other major organs must be working well enough (confirm with trial site for specific requirements)
Who may not be able to join:
- You have had another cancer in the past 5 years, unless it was a cured skin cancer (basal cell), a very early-stage bladder cancer, or a pre-cancerous condition of the breast or cervix
- You have previously received a KRAS cancer vaccine
- You have needed immune-suppressing or immune-modifying medications within 4 weeks before starting the trial, or you have a condition — including a history of organ transplant — that requires you to take such medications
- You have a known allergy to any ingredient in the study drug
- You have an uncontrolled infection in your body, or you have active tuberculosis (TB)
- You have serious heart or blood vessel disease
- You have brain metastases (cancer that has spread to the brain) that are causing symptoms or still need treatment — people with brain metastases that are not causing symptoms and do not need treatment may still be eligible
- You have an active autoimmune or inflammatory disease (where your immune system attacks your own body)
- You have a history of severe allergic reactions, uncontrolled eczema, or uncontrolled asthma
- You have other serious medical conditions (confirm with trial site for details)
- You have previously had an organ transplant, bone marrow transplant, or stem cell transplant
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Baiyong Shen, Ruijin Hospital
Phone: 18817821319
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Part I: The incidence and nature of dose-limiting toxicity (DLT) for ABO2102 as monotherapy or in combination with toripalilmab.; Part I: The incidence and severity of treatment-emergent adverse events (TEAE)s.; Part I: The incidence and severity of serious TEAEs (TESAE)s.; Part I: The incidence and severity of TEAEs leading to interruption or early termination of study treatment.; Part II: Overall Response Rate (ORR) per RECIST version 1.1.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.